Autoimmune Diseases

Women With HIV and Persistent Depression May Experience Greater Risk for Heart Disease

July 03, 2020

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.

Studies Reveal Positive Results for Infliximab Biosimilar

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

Prescription Fills Surge for Hydroxychloroquine, Chloroquine During Pandemic

June 04, 2020

A recent analysis showed a surge in prescription fills for hydroxychloroquine/chloroquine, likely due to off-label prescribing for coronavirus disease 2019. 

FDA Approves Ixekizumab for Non-radiographic Axial Spondyloarthritis

June 03, 2020

Ixekizumab (Taltz, Eli Lilly) is the first interleukin-17A antagonist to be approved for non-radiographic axial spondyloarthritis.

New Oral Treatment for Relapsing Forms of Multiple Sclerosis Now Available

June 03, 2020

Bristol Myers Squibb announced the commercial US launch of ozanimod (Zeposia) for the treatment of relapsing forms of multiple sclerosis.

Filgotinib Trial Shows Positive Results in Ulcerative Colitis

May 26, 2020

Filgotinib achieved all primary end points of the phase 2b/3 study in patients with moderate-to-severe ulcerative colitis.

FDA Approves Dupilumab for Atopic Dermatitis in Children

May 26, 2020

Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.

Phase 3 Study: Apremilast Shows Efficacy in Mild-to-Moderate Plaque Psoriasis

May 08, 2020

Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.

Rituximab Biosimilar Now Available in United States for Rheumatoid Arthritis

May 04, 2020

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Early Treatment with Ocrelizumab Reduces Disability Risk by Nearly Half in Relapsing MS

April 28, 2020

Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis. 

x